Credit Suisse Group initiated coverage on shares of Gilead Sciences (NASDAQ:GILD) in a research report released on Monday morning, 24/7 WallStreet reports. The firm issued a neutral rating and a $70.00 price objective on the biopharmaceutical company’s stock.

Several other brokerages also recently commented on GILD. Wells Fargo & Co lowered their price objective on shares of Gilead Sciences from $95.00 to $89.00 and set an outperform rating for the company in a research report on Tuesday, February 5th. Citigroup restated a buy rating and set a $100.00 price objective on shares of Gilead Sciences in a research report on Tuesday, February 5th. BidaskClub downgraded shares of Gilead Sciences from a buy rating to a hold rating in a research report on Thursday, February 7th. Zacks Investment Research downgraded shares of Gilead Sciences from a hold rating to a sell rating in a research report on Wednesday, January 23rd. Finally, JPMorgan Chase & Co. restated a buy rating and set a $87.00 price objective on shares of Gilead Sciences in a research report on Tuesday, May 7th. Nine investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average price target of $81.00.

Shares of GILD opened at $66.50 on Monday. Gilead Sciences has a one year low of $60.32 and a one year high of $79.61. The company has a market cap of $84.60 billion, a price-to-earnings ratio of 10.81, a PEG ratio of 0.81 and a beta of 1.14. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.62 and a quick ratio of 3.53.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.53 by $0.23. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The business had revenue of $5.28 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same period in the previous year, the business earned $1.48 earnings per share. The company’s revenue was up 3.8% on a year-over-year basis. On average, sell-side analysts anticipate that Gilead Sciences will post 6.6 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be paid a $0.63 dividend. The ex-dividend date is Thursday, June 13th. This represents a $2.52 annualized dividend and a dividend yield of 3.79%. Gilead Sciences’s dividend payout ratio is 40.98%.

In other Gilead Sciences news, Director Richard James Whitley sold 9,534 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $65.48, for a total transaction of $624,286.32. Following the sale, the director now owns 34,669 shares of the company’s stock, valued at $2,270,126.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John Francis Cogan sold 2,700 shares of the company’s stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $64.14, for a total transaction of $173,178.00. Following the sale, the director now directly owns 57,560 shares in the company, valued at approximately $3,691,898.40. The disclosure for this sale can be found here. In the last three months, insiders sold 28,602 shares of company stock worth $1,863,445. 0.20% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Gradient Investments LLC raised its holdings in shares of Gilead Sciences by 16.1% during the fourth quarter. Gradient Investments LLC now owns 1,076 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 149 shares during the period. Lenox Wealth Management Inc. raised its holdings in shares of Gilead Sciences by 1.8% in the 1st quarter. Lenox Wealth Management Inc. now owns 9,059 shares of the biopharmaceutical company’s stock worth $589,000 after acquiring an additional 156 shares during the last quarter. Vectors Research Management LLC raised its holdings in shares of Gilead Sciences by 6.3% in the 4th quarter. Vectors Research Management LLC now owns 2,651 shares of the biopharmaceutical company’s stock worth $166,000 after acquiring an additional 157 shares during the last quarter. Creative Financial Designs Inc. ADV raised its holdings in shares of Gilead Sciences by 55.9% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 165 shares during the last quarter. Finally, Rathbone Brothers plc raised its holdings in shares of Gilead Sciences by 3.1% in the 1st quarter. Rathbone Brothers plc now owns 5,547 shares of the biopharmaceutical company’s stock worth $361,000 after acquiring an additional 167 shares during the last quarter. 79.94% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Story: What are different types of coverage ratios?

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.